News

9/29/2010:

Nuon Therapeutics Announces Gout Program Study Results to be Presented at the American College of Rheumatology

06/22/2010:

Nuon Therapeutics Announces Results of Studies Confirming the Uric Acid Lowering Activity of Tranilast

06/16/2010:

Nuon Therapeutics Announces Positive Topline Results From a Phase 2a Study in Hyperuricemia

06/03/2010:

Nuon Therapeutics Announces Data Demonstrating Uric Acid Lowering Activity of Tranilast To Be Presented at EULAR 2010

05/13/2010:

Nuon Therapeutics Names Lee Rauch Chief Executive Officer

04/29/2010:

Nuon Therapeutics To Present Update On Programs In Rheumatoid Arthritis and Gout at 2010 BIO International Convention

04/21/2010:

Nuon Therapeutics Identifies Novel Use and Advances NU1618 into Development for Chronic Hyperuricemia in Patients with Gout

10/12/2009:

Nuon Therapeutics To Present At Biopartnering Europe

07/16/2009:

Affymax CEO Arlene Morris Joins Nuon Therapeutics’ Board of Directors as Chair

07/16/2009:

Nuon Therapeutics Appoints Paulette Dillon, Chief Business Officer, and Tito Serafini, Chief Scientific Officer

January 5, 2009

Nuon Therapeutics, Inc. Names Michael M. Kitt, M.D., Chief Medical Officer

April 28, 2008

Nuon Therapeutics, Inc. Completes $27 Million Series B Financing

July 23, 2007

Nuon Therapeutics, Inc. Completes Licensing, Supply And Collaboration Agreement On Tranilast With Kissei Pharmaceutical Co., Ltd.

July 20, 2007

Biotechnology Start-Up Nuon Therapeutics, Inc. Completes $5 Million Series A Financing And Names Management Team